Plain-English translation of NCT04592211 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing whether combining three medications—pembrolizumab, olaparib, and paclitaxel—can help treat advanced stomach cancer that has progressed despite previous treatment. Pembrolizumab works by helping your immune system recognize and fight cancer cells. Olaparib targets cancer cells by blocking a repair protein they depend on. Paclitaxel is a chemotherapy drug that kills cancer cells directly. This study will evaluate whether these three medications work better together than existing options.
Stomach cancer that has already been treated and comes back is very difficult to manage, and current second-line treatments have limited effectiveness. Researchers believe combining these three medications—each working in a different way—might offer better results for patients whose cancer has returned.
You likely qualify if…
You likely don't qualify if…
You would receive the three medications as part of ongoing outpatient treatment, likely through regular clinic visits where you would take pills by mouth and may receive some medications by injection or infusion. Your doctors would monitor you closely with blood tests and imaging scans to see how well the treatment is working and to watch for side effects. The study involves two phases: a Phase 1b phase to establish the right dose, and a Phase 2 phase to test how well the treatment works overall.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
South Korea